Literature DB >> 11583972

Plasma apolipoprotein(a) co-deposits with fibrin in inflammatory arthritic joints.

N Busso1, J Dudler, R Salvi, V Péclat, V Lenain, S Marcovina, R Darioli, P Nicod, A K So, V Mooser.   

Abstract

Extravascular coagulation and diminished fibrinolysis are processes that contribute to the pathology of both inflammatory arthritis and atherosclerosis. We hypothesized that, given its homology with plasminogen, apolipoprotein (apo) (a), the distinctive glycoprotein of the atherogenic lipoprotein (Lp) (a), may be equally implicated in inflammatory arthritis. We detected the presence of apo(a) as part of Lp(a) in human arthritic synovial fluid. The abundance of apo(a) in synovial fluid rose in proportion to plasma apo(a) levels and was higher in inflammatory arthritides than in osteoarthritis. In addition, apo(a) immunoreactive material, but not apo(a) transcripts, was detected in inflammatory arthritic synovial tissues. These data indicated that synovial fluid apo(a) originates from circulating Lp(a) and that diffusion of Lp(a) through synovial tissue is facilitated in inflammatory types of arthritis. In synovial tissues, apo(a) co-localized with fibrin. These observations could be reproduced in a model of antigen-induced arthritis, using transgenic mice expressing human Lp(a). Although in this mouse model the presence of apo(a) did not change the severity of arthritis, the co-localization of apo(a) with fibrin in synovial tissue suggests that, in humans, apo(a) may modulate locally the fibrinolytic activity and may thus contribute to the persistence of intra-articular fibrin in inflammatory arthritis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11583972      PMCID: PMC1850502          DOI: 10.1016/S0002-9440(10)62531-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  Hypercoagulability and hypofibrinolysis in primary osteoarthritis.

Authors:  P A Cheras; A N Whitaker; E A Blackwell; T J Sinton; M D Chapman; K A Peacock
Journal:  Clin Orthop Relat Res       Date:  1997-01       Impact factor: 4.176

2.  Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints.

Authors:  N Busso; V Péclat; A So; A P Sappino
Journal:  Ann Rheum Dis       Date:  1997-09       Impact factor: 19.103

3.  Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis.

Authors:  Y Asanuma; S Kawai; H Aoshima; J Kaburaki; Y Mizushima
Journal:  Arthritis Rheum       Date:  1999-03

4.  Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden.

Authors:  S Wallberg-Jonsson; M L Ohman; S R Dahlqvist
Journal:  J Rheumatol       Date:  1997-03       Impact factor: 4.666

5.  The contribution of synovial fluid lipoproteins to the chronic synovitis of rheumatoid arthritis.

Authors:  P E Prete; A Gurakar-Osborne
Journal:  Prostaglandins       Date:  1997-10

6.  Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a).

Authors:  D A Sanan; D L Newland; R Tao; S Marcovina; J Wang; V Mooser; R E Hammer; H H Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  1998-04-14       Impact factor: 11.205

7.  Polymorphonuclear cells isolated from human peripheral blood cleave lipoprotein(a) and apolipoprotein(a) at multiple interkringle sites via the enzyme elastase. Generation of mini-Lp(a) particles and apo(a) fragments.

Authors:  C Edelstein; J A Italia; A M Scanu
Journal:  J Biol Chem       Date:  1997-04-25       Impact factor: 5.157

8.  Low density lipoprotein of synovial fluid in inflammatory joint disease is mildly oxidized.

Authors:  M J James; D van Reyk; K A Rye; R T Dean; L G Cleland; P J Barter; W Jessup
Journal:  Lipids       Date:  1998-11       Impact factor: 1.880

9.  Exacerbation of antigen-induced arthritis in urokinase-deficient mice.

Authors:  N Busso; V Péclat; K Van Ness; E Kolodziesczyk; J Degen; T Bugge; A So
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

10.  Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well.

Authors:  D P Symmons; M A Jones; D L Scott; P Prior
Journal:  J Rheumatol       Date:  1998-06       Impact factor: 4.666

View more
  5 in total

1.  Ethnicity may be a reason for lipid changes and high Lp(a) levels in rheumatoid arthritis.

Authors:  Mustafa Cesur; Zeynep Ozbalkan; Mehtap Akcil Temel; Yaşar Karaarslan
Journal:  Clin Rheumatol       Date:  2006-05-06       Impact factor: 2.980

2.  A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis.

Authors:  I Missala; U Kassner; E Steinhagen-Thiessen
Journal:  Int J Rheumatol       Date:  2012-12-05

3.  Apolipoprotein-A1 as a damage-associated molecular patterns protein in osteoarthritis: ex vivo and in vitro pro-inflammatory properties.

Authors:  Dominique de Seny; Gaël Cobraiville; Edith Charlier; Sophie Neuville; Laurence Lutteri; Caroline Le Goff; Denis Malaise; Olivier Malaise; Jean-Paul Chapelle; Biserka Relic; Michel G Malaise
Journal:  PLoS One       Date:  2015-04-07       Impact factor: 3.240

4.  Association of Serum Low-Density Lipoprotein, High-Density Lipoprotein, and Total Cholesterol With Development of Knee Osteoarthritis.

Authors:  Jessica L Schwager; Michael C Nevitt; James Torner; Cora E Lewis; Nirupa R Matthan; Na Wang; Xianbang Sun; Alice H Lichtenstein; David Felson
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-01-08       Impact factor: 4.794

5.  Comparative analysis of synovial fluid and plasma proteomes in juvenile arthritis--proteomic patterns of joint inflammation in early stage disease.

Authors:  David S Gibson; Sarah Blelock; Jim Curry; Sorcha Finnegan; Adrienne Healy; Catriona Scaife; Catherine McAllister; Stephen Pennington; Michael Dunn; Madeleine Rooney
Journal:  J Proteomics       Date:  2009-05-02       Impact factor: 4.044

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.